BPA - HPLC/UHPLC and GC-MS Systems
Past New Requirement Updated
- Agency
-
Food and Drug Administration
Department of Health and Human Services
- Solicitation expected
- Estimated value
- $7,000,000 to $13,000,000
- Set-aside
- No set-aside
Forecast facts
- Anticipated award
- NAICS code
- 334516 Analytical Laboratory Instrument Manufacturing
- Points of contact
-
- HFP Acquisition Liaison hfpacquisitions@fda.hhs.gov
Forecast details come from HHS's procurement forecast. Agencies' dates and values are estimates.
About this forecast
The Food and Drug Administration is forecasting a new Blanket Purchase Agreement (BPA) for HPLC/UHPLC and GC-MS analytical laboratory systems to support the Office of Laboratory Operations and Analysis Services (OLOAS). The procurement aims to enhance laboratory operations through improved sample throughput, faster analysis times, multi-sample processing capabilities, and advanced chemical analysis methodologies including multi-residue screening and targeted quantitative methods. The solicitation is estimated to release on December 1, 2025, with an anticipated award date of June 1, 2026.
The estimated award value ranges from $7,000,000 to $13,000,000 for a base contract plus four option years. The modernized instrumentation will strengthen analytical result quality, sensitivity, selectivity, and reliability to support FDA's regulatory decision-making processes and reduce sample turnaround times. Inquiries regarding this opportunity should be directed to the Food and Drug Administration's Acquisition Liaison at hfpacquisitions@fda.hhs.gov.
Forecast text
BPA - HPLC/UHPLC and GC-MS Systems
Base + 4 OY
The acquisition of new HPL>C/UHPLC and GC-MS systems will provide several benefits to OLOAS operations. First these advanced instruments will increase sample throughput by enabling faster analysis times and the capability to process multiple samples simultaneously. Second, the new system will enhance OLOAS laboratory's efficiency and speed in conducting complex chemical analyses, including multi-residue screening and targeted quantitative methods. Third, the improved instrumentation will lead to an overall enhanced sample flow process for regulatory samples, reducing turnaround times and enabli8ng more rapid regulatory decision-making. Additionally, modern HPLC/UHPLC and GC-MS systems offer improved sensitivity, selectivity, and reliability, which will strengthen the quality and defensibility of analytical results supporting FDA's regulatory actions.
On GovTribe
Work this forecast
- Track it in your pipeline
- Find teaming partners
- Similar forecasts
- Ask GovTribe AI about this forecast